TY  - JOUR
T1  - GUidelines for treatment of anthrax—reply
AU  - Inglesby T, O'Toole T
Y1  - 2002/10/16
N1  - 10.1001/jama.288.15.1845
JO  - JAMA
SP  - 1848
EP  - 1849
VL  - 288
IS  - 15
N2  - 
Meyerhoff and Murphy emphasize that ciprofloxacin has been approved
by the FDA for both children and adults for postexposure prophylaxis for inhalational
anthrax. They also state that the FDA has not approved any therapy specifically
for the treatment of inhalational anthrax while "penicillin G procaine and
doxycycline are both approved by the FDA for the treatment of disease due
to B anthracis, as well as for anthrax PEP. Ciprofloxacin
is only approved for "inhalational anthrax (postexposure)" and is not approved
by the FDA for the treatment of inhalational anthrax." At this time, then,
clinicians have no options that have been approved by the FDA for the treatment
of inhalational anthrax. In the absence of FDA approval for any specific treatment
for inhalational anthrax, clinicians must rely on other sources of guidance
regarding treatment recommendations for this disease process.

SN  - 0098-7484
M3  - doi: 10.1001/jama.288.15.1845
UR  - http://dx.doi.org/10.1001/jama.288.15.1845
ER  -